RARX News and Press, Ra Pharmaceuticals Inc.

Investment Thesis The patent disputes over its leading revenue generator have taken its toll on Alexion Pharmaceuticals, Inc. ( ALXN ), with its share price lagging the peers as the company attempts to diversify the top-line. The recent acquisitions, driven by the rising cash flows and low...

This article is part of a series that provides an ongoing analysis of the changes made to Prem Watsa's 13F portfolio on a quarterly basis. It is based on Watsa's regulatory 13F Form filed on 05/15/2020. Please visit our Tracking Prem Watsa's Fairfax Financial Holdings Portfolio series to g...

On the heels of its meeting with the FDA, Apellis Pharmaceuticals (NASDAQ: APLS ) announces that it expects to file a marketing application in H2 seeking approval of pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease in which the immune sys...

Since Part I , the S&P 500 ( SPY ) has declined to a point where it worth reassessing. Updated Valuation Its CAPE ratio declined from over 30, where it reached only briefly for a moment before the Great Depression, tech bubble, and Covid-19. At 23 today, it is still somewhat higher ...

Background According to a recent study by Gartner, average duration to finalize a merger or acquisition from the time of public announcement has risen more than 30 percent in the last decade. Gartner analyzed more than 23000 deals among S&P1200 companies since 2010 to come up with th...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) is joining forces with 30 million healthcare advocates around the world for the 13 th Annual Rare Disease Day ® , an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people l...

Ra Pharmaceuticals (NASDAQ: RARX ): Q4 GAAP EPS of -$0.79 misses by $0.16 . More news on: Ra Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Enrollment ongoing in Phase 3 clinical trial of zilucoplan in gMG, with top-line results expected in early 2021 First patient dosed in Phase 2 clinical trial of zilucoplan in IMNM, with top-line results expected in the second half of 2020 IND cleared by FDA for the HEALEY ALS Plat...

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its Board of Direc...

Pivotal Phase 3 trial of zilucoplan in gMG ongoing, with top-line results expected in early 2021 Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that full results from its Phase 2 clinical trial of zilucoplan in patients with generalized myasthenia gravis (gMG) were published ...